Background
==========

Two direct-acting antiviral compounds, boceprevir and telaprevir, have recently been approved by drug regulatory boards in North America and Europe to treat adults with chronic hepatitis C virus genotype 1 infection.[@b1-tcrm-8-105]--[@b3-tcrm-8-105] Boceprevir and telaprevir prevent hepatitis C viral replication by inhibiting the activity of protease NS3/4A.[@b4-tcrm-8-105] Clinical trials demonstrate that boceprevir or telaprevir in combination with pegylated interferon (peginterferon) alpha and ribavirin dramatically improve treatment efficacy in both treatment-naïve patients (those who have not received any drug therapy for their hepatitis C virus infection)[@b5-tcrm-8-105]--[@b10-tcrm-8-105] and treatment-experienced patients (those who have previously been treated for hepatitis C virus and did not achieve a sustained virologic response to the therapy),[@b11-tcrm-8-105]--[@b14-tcrm-8-105] when compared to conventional peginterferon alpha and ribavirin therapy. Currently, there is no direct evidence to establish if boceprevir or telaprevir offer therapeutic advantages over one another. To this end, the relative efficacy and safety of boceprevir and telaprevir, when used in combination with peginterferon alpha and ribavirin, were examined using a direct and indirect meta-analysis of the currently published evidence.

Methods
=======

Eligibility criteria
--------------------

Published phase II or phase III randomized placebo-controlled trials examining the efficacy and safety of boceprevir and telaprevir in hepatitis C virus genotype 1 infected adult populations were included. Trials had to include these direct-acting drugs in addition to peginterferon alpha and ribavirin. No limitation on treatment duration was set. Therefore, trials could include standard dose-duration regimens (where boceprevir is provided in weeks 4--48 of a 48-week treatment duration or telaprevir is provided in weeks 1--12 of a 48-week treatment duration), response-guided therapy regimens, and any other treatment dose-duration regimens. Both treatment-naïve and treatment-experienced populations were included. Trials that reported only on dosing strategies of the individual drugs without a comparison to a control were excluded.

Search strategy
---------------

In consultation with a medical librarian, a systematic search of the literature was conducted. Two broad and sensitive searches were conducted, one including only the term "boceprevir," the other including only the term "telaprevir." Each search was limited to clinical trials in humans. Searches were not limited by language, sex, or age. Two investigators (EM, ED) independently searched each of the following ten databases (from inception to week 40 \[October 3--9, 2011\]): MEDLINE, Embase, Cochrane Central Register of Controlled Trials, AMED, CINAHL, TOXNET, Development and Reproductive Toxicology, Hazardous Substances Data Bank, PsycINFO, and Web of Science. The bibliographies of published systematic and narrative reviews and relevant included trials were also searched. Where necessary, industry was also contacted for assistance in identifying completed clinical trials.

Study selection
---------------

Two investigators (EM, ED) working independently, in duplicate, scanned all abstracts and obtained the full text reports of records indicating that the study was a randomized placebo-controlled trial that examined the efficacy and safety of boceprevir or telaprevir in adult populations. After obtaining full reports of the candidate studies, the same reviewers independently assessed eligibility via full text review. Where required, a third clinician reviewer (CC) provided arbitration.

Data abstraction and endpoints
------------------------------

Two investigators (EM, ED) working independently, in duplicate, abstracted data on the primary outcomes of interest: the proportion of patients achieving sustained virologic response (defined as an undetectable hepatitis C virus ribonucleic acid \[RNA\] at the end of the 24-week post therapy follow-up period), the proportion of patients relapsing (defined as a reoccurrence of hepatitis C virus RNA within the 24-week post therapy follow-up period), and the proportion of patients discontinuing treatment (defined as the discontinuation of all assigned study drugs during the set treatment period).

Outcomes data were extracted for both treatment-naïve patients (generally defined as patients with no exposure to peginterferon alpha plus ribavirin) and treatment-experienced patients (generally defined as patients with prior exposure to peginterferon alpha plus ribavirin), and the subgroups of patients with compensated cirrhosis, prior relapse (generally defined as patients who had a full decrease in hepatitis C viral load after peginterferon alpha plus ribavirin treatment, but a subsequent reoccurrence of the virus during the 24-week follow-up period after the end of treatment), and prior nonresponse (generally defined as patients who did not achieve a decrease in hepatitis C viral load during peginterferon alpha plus ribavirin treatment or a partial decrease in hepatitis C viral load during peginterferon alpha plus ribavirin treatment). Data was also abstracted for commonly reported adverse events: anemia (generally defined as hemoglobin less than 100 g/L), neutropenia (generally defined as absolute neutrophil count less than 0.75 10^9^/L), rash (any, as reported by site investigators), and pruritus (any, as reported by site investigators). Furthermore, trial characteristics (ie, interventions, treatment doses, treatment durations) and participant baseline characteristics (ie, age, sex, genosubtype) were abstracted.

Data analysis
-------------

In order to assess interrater reliability on inclusion of articles, the phi statistic was calculated, which was first developed to provide a measure of interobserver agreement independent of chance.[@b15-tcrm-8-105] Pairwise meta-analysis of all trial evidence using a DerSimonian--Laird random effects model, which recognizes and anchors studies as a sample of all potential studies, and incorporates an additional between-study component to the estimate of variability, thus placing additional weighting on the smaller studies.[@b16-tcrm-8-105],[@b17-tcrm-8-105] When more than two trial arms could be pooled, heterogeneity in the pairwise estimates was assessed using the I^2^ statistic as a measure of the proportion of the overall variation that is attributable to between-study heterogeneity.[@b18-tcrm-8-105] As there were no direct (head-to-head) evaluations of boceprevir versus telaprevir, the adjusted indirect comparison statistic, first described by Bucher et al,[@b19-tcrm-8-105] was used. The adjusted indirect comparison utilized the evidence on boceprevir versus peginterferon plus ribavirin and the evidence on telaprevir versus peginterferon plus ribavirin to produce an estimate of comparative effectiveness between boceprevir and telaprevir. Meta-regression analysis of the indirect evidence was performed to explore whether the results from the indirect comparisons were robust to changes in the two trial baseline characteristics, type of peginterferon given (alpha-2a \[peg-2a\] or alpha-2b \[peg-2b\]), and treatment experience (naïve or experienced). Peginterferon type and treatment experience were included in the model for the primary meta-regression and each of the two covariates alone was included as a sensitivity analysis. For all analyses, relative risk was used as the primary effect estimate with 95% confidence intervals (CIs) for each.

As a sensitivity analysis, a Bayesian multiple treatment meta-analysis was applied.[@b20-tcrm-8-105] For treatment-naïve patients, four trials from a previous review[@b21-tcrm-8-105] that compared peg-2a with peg-2b were identified. To control for the fact that telaprevir had only been compared to peg-2a and boceprevir had only been compared to peg-2b among treatment-naïve patients, the comparison of peg-2a versus peg-2b was additionally included in the treatment network and a conventional random-effects multiple treatment comparison was carried out. For treatment-experienced patients, only one trial from a previous review that compared peg-2a with peg-2b was identified.[@b21-tcrm-8-105] With only one trial informing this comparison, and only one trial informing telaprevir versus peg-2a, it was not possible to run a Bayesian multiple treatment comparison. Therefore, a conventional frequentist adjusted indirect comparison including the peg-2a versus peg-2b comparison was performed.

The main analyses considered the three outcomes: sustained virologic response, relapse, and treatment discontinuation. The subgroup analyses used the same outcomes, where possible, but were restricted first to cirrhotic patients and then second to prior relapse and prior nonresponders. The adverse events analyses included anemia, neutropenia, rash, and pruritus as outcomes. Each analysis was conducted among two experimental settings: standard-dose duration (where boceprevir is provided in weeks 4--48 of a 48-week treatment duration or telaprevir is provided in weeks 1--12 of a 48-week treatment duration) and response-guided therapy, and was analyzed separately for treatment-naïve and treatment-experienced patients, with the exception of prior relapse and prior nonresponse patients who were all treatment-experienced. As a sensitivity analysis for the main analyses, all available boceprevir arms and telaprevir arms among naïve or experienced groups were examined. Analyses were conducted using StatsDirect version 2.5.2 (StatsDirect Ltd, Cheshire, United Kingdom) and R version 2.12.2.[@b22-tcrm-8-105]

Results
=======

Included studies
----------------

Ten published phase II and III randomized placebo-controlled trials provided efficacy and safety data among 5072 patients treated with boceprevir or telaprevir in combination with peginterferon alpha plus ribavirin. Interobserver agreement was very good (phi = 0.91). Four of the trials provided data among those treated with boceprevir and peginterferon alpha plus ribavirin combinations[@b5-tcrm-8-105],[@b6-tcrm-8-105],[@b11-tcrm-8-105],[@b12-tcrm-8-105] (two of these trials were conducted in treatment-naïve populations[@b5-tcrm-8-105],[@b6-tcrm-8-105] and two were conducted in treatment-experienced populations[@b11-tcrm-8-105],[@b12-tcrm-8-105]) and six of the trials provided data among those treated with telaprevir and peginterferon alpha plus ribavirin combinations[@b7-tcrm-8-105]--[@b10-tcrm-8-105],[@b13-tcrm-8-105],[@b14-tcrm-8-105] (four of these trials were conducted in treatment-naïve populations[@b7-tcrm-8-105]--[@b10-tcrm-8-105] and two were conducted in treatment-experienced populations[@b13-tcrm-8-105],[@b14-tcrm-8-105]). [Tables 1](#t1-tcrm-8-105){ref-type="table"} and [2](#t2-tcrm-8-105){ref-type="table"} provide the characteristics of these included trials. The populations were effectively comparable in terms of age, gender, and race. In terms of genosubtype, Kumada et al[@b10-tcrm-8-105] was an exception with a population that was predominantly genosubtype 1b; genosubtype 1a was most common among the populations recruited in all other trials. Fifteen trials identified in the search were excluded because they analyzed data from phase I trials,[@b23-tcrm-8-105]--[@b34-tcrm-8-105] or they were not placebo-controlled.[@b35-tcrm-8-105],[@b36-tcrm-8-105] [Figure 1](#f1-tcrm-8-105){ref-type="fig"} shows a schematic of the study selection process.

Standard dose-duration boceprevir or telaprevir among all patients
------------------------------------------------------------------

All four randomized placebo-controlled boceprevir trials (two conducted among treatment-naïve patients and two conducted among treatment-experienced patients) included standard dose-duration trial arms,[@b5-tcrm-8-105],[@b6-tcrm-8-105],[@b11-tcrm-8-105],[@b12-tcrm-8-105] and three randomized placebo-controlled telaprevir trials (two conducted among treatment-naïve patients and one conducted among treatment-experienced patients) included standard dose-duration trial arms.[@b8-tcrm-8-105],[@b9-tcrm-8-105],[@b14-tcrm-8-105]

[Tables 3](#t3-tcrm-8-105){ref-type="table"} and [4](#t4-tcrm-8-105){ref-type="table"} show the results of the direct comparison between standard dose-duration regimens of telaprevir or boceprevir coadministered with peginterferon alpha plus ribavirin (intervention) and placebo coadministered with peginterferon alpha plus ribavirin (control). The results indicate that naïve and experienced patients treated with a standard dose-duration regimen of boceprevir or telaprevir in combination with peginterferon alpha plus ribavirin are generally more likely to achieve a sustained virologic response, less likely to relapse to treatment, and less likely to discontinue treatment when compared to those treated with peginterferon alpha plus ribavirin alone.

[Table 5](#t5-tcrm-8-105){ref-type="table"} shows the results of the indirect comparison between standard-dose duration regimens of boceprevir coadministered with peginterferon alpha plus ribavirin and standard-dose duration regimens of telaprevir coadministered with peginterferon alpha plus ribavirin. The results indicate that there are no differences between standard dose-duration regimens of boceprevir and telaprevir in terms of sustained virologic response, relapse to treatment, and discontinuation of treatment. [Figures 2](#f2-tcrm-8-105){ref-type="fig"} and [3](#f3-tcrm-8-105){ref-type="fig"} graphically display results using a forest plot.

Response-guided durations that included boceprevir or telaprevir among all patients
-----------------------------------------------------------------------------------

Two randomized placebo-controlled boceprevir trials (one conducted among treatment-naïve patients and one conducted among treatment-experienced patients) included response-guided therapy arms,[@b5-tcrm-8-105],[@b11-tcrm-8-105] and one randomized placebo- controlled telaprevir trial (conducted among treatment-naïve patients) included response-guided therapy arms.[@b8-tcrm-8-105]

[Tables A](#t9-tcrm-8-105){ref-type="table"} and [B in the Appendix](#t10-tcrm-8-105){ref-type="table"} show the results of the direct comparison between response-guided therapy regimens of telaprevir or boceprevir coadministered with peginterferon alpha plus ribavirin (intervention) and placebo coadministered with peginterferon alpha plus ribavirin (control). The results indicate that naïve and experienced patients receiving a response-guided therapy regimen consisting of boceprevir or telaprevir in combination with peginterferon alpha plus ribavirin are generally more likely to achieve a sustained virologic response, less likely to relapse to treatment, and less likely to discontinue treatment when compared to those treated with peginterferon alpha plus ribavirin alone.

[Table 6](#t6-tcrm-8-105){ref-type="table"} shows the results of the indirect comparison between response-guided therapy regimens of boceprevir coadministered with peginterferon alpha plus ribavirin and response-guided therapy regimens of telaprevir coadministered with peginterferon alpha plus ribavirin. The results indicate that there are no differences between boceprevir and telaprevir in terms of sustained virologic response, relapse to treatment, and discontinuation of treatment for naïve patients treated with a response-guided regimen. No trials included treatment-experienced patients treated with a response-guided therapy regimen of telaprevir; and therefore, a comparison could not be made for this group. [Figure 4](#f4-tcrm-8-105){ref-type="fig"} graphically displays the results using a forest plot.

Sensitivity analysis
--------------------

### All dose-durations of boceprevir or telaprevir among all patients

All four randomized placebo-controlled boceprevir trials[@b5-tcrm-8-105],[@b6-tcrm-8-105],[@b11-tcrm-8-105],[@b12-tcrm-8-105] and all six randomized placebo-controlled telaprevir trials[@b7-tcrm-8-105]--[@b10-tcrm-8-105],[@b13-tcrm-8-105],[@b14-tcrm-8-105] contributed to the analysis of all dose-durations combined.

[Tables C](#t11-tcrm-8-105){ref-type="table"}--[F in the Appendix](#t14-tcrm-8-105){ref-type="table"} show the results of the direct comparison between all dose-durations of telaprevir or boceprevir coadministered with peginterferon alpha plus ribavirin (intervention) and placebo coadministered with peginterferon alpha plus ribavirin (control). The results indicate that, in general, naïve and experienced patients treated with boceprevir or telaprevir in combination with peginterferon alpha plus ribavirin are more likely to achieve a sustained virologic response, less likely to relapse to treatment, and less likely to discontinue treatment when compared to those treated with peginterferon alpha plus ribavirin alone.

Indirect comparisons suggest that experienced patients treated with boceprevir at any point in a 48-week treatment course are more likely to relapse compared to experienced patients treated with telaprevir ([Table G, Appendix](#t15-tcrm-8-105){ref-type="table"}). However, closer inspection of the results reveals that this finding is driven by a large absolute difference in relapse among the control arms rather than the treatment arms ([Tables C](#t11-tcrm-8-105){ref-type="table"} and [D, Appendix](#t12-tcrm-8-105){ref-type="table"}). No other differences were observed between boceprevir and telaprevir for all dose-durations ([Tables G](#t15-tcrm-8-105){ref-type="table"} and [H, Appendix](#t16-tcrm-8-105){ref-type="table"}).

Multiple treatment comparison
-----------------------------

The multiple treatment comparison of the primary outcome for naïve patients showed an almost identical result to the frequentist method (1.34, 95% creditable interval 0.46--4.03). Given the sparseness of the network, it was not possible to apply a Bayesian approach to the experienced patients.

Meta-regression
---------------

For sustained virologic response, the meta-regression analysis of the indirect evidence demonstrated that the magnitude of effect significantly depends on whether patients are treatment-naïve or treatment-experienced (RR 1.96, 95% CI 1.60--2.42), but not the type of peginterferon alpha used (RR 1.12, 95% CI 0.84--1.55). Controlling for both variables, no significant difference was detected for boceprevir versus telaprevir (RR 1.12, 95% CI 0.82--1.52). For relapse, no significant difference was detected for treatment-naïve or treatment-experienced patients (RR 0.88, 95% CI 0.31--2.47) or type of peginterferon alpha (RR 0.79, 95% CI 0.17--3.70). Controlling for both variables, no significant difference was detected for boceprevir versus telaprevir (RR 0.80, 95% CI 0.17--3.75). For discontinuation, no significant difference was detected for treatment-naïve or treatment-experienced patients (RR 0.76, 95% CI 0.36--1.61) or type of peginterferon alpha (RR 0.82, 95% CI 0.27--2.51). Controlling for both variables, no significant difference was detected for boceprevir versus telaprevir (RR 1.07, 95% CI 0.35--3.27). Sensitivity meta-regression analyses using only one covariate in the model yielded similar results to the model including both covariates.

Subgroups
---------

### Standard dose-durations of boceprevir or telaprevir among patients with compensated cirrhosis

All four randomized placebo-controlled boceprevir trials (two conducted among treatment-naïve patients and two conducted among treatment-experienced patients)[@b5-tcrm-8-105],[@b6-tcrm-8-105],[@b11-tcrm-8-105],[@b12-tcrm-8-105] and two randomized placebo-controlled telaprevir trials (one conducted among treatment-naïve patients and one conducted among treatment-experienced patients)[@b8-tcrm-8-105],[@b14-tcrm-8-105] included data on sustained virologic response among compensated cirrhosis patients treated with standard dose-duration. Relapse and discontinuation data was not available for compensated cirrhosis patients treated with standard dose-durations.

[Tables I](#t17-tcrm-8-105){ref-type="table"} and [J in the Appendix](#t18-tcrm-8-105){ref-type="table"} show the results of the direct comparison between standard dose-duration regimens of telaprevir or boceprevir coadministered with peginterferon alpha plus ribavirin (intervention) and placebo coadministered with peginterferon alpha plus ribavirin (control) for patients with compensated cirrhosis. The results indicate that, in general, those treated with standard dose-duration boceprevir or telaprevir in combination with peginterferon alpha plus ribavirin are generally more likely to achieve a sustained virologic response when compared to those treated with peginterferon alpha plus ribavirin alone.

[Table K in the Appendix](#t19-tcrm-8-105){ref-type="table"} shows the results of the indirect comparison between standard dose-duration regimens of boceprevir coadministered with peginterferon alpha plus ribavirin and standard dose-duration regimens of telaprevir coadministered with peginterferon alpha plus ribavirin for patients with compensated cirrhosis. The results show that there are no differences between standard dose-duration regimens of boceprevir and telaprevir among patients with compensated cirrhosis.

### Response-guided therapy durations that included boceprevir or telaprevir among patients with compensated cirrhosis

Two randomized placebo-controlled boceprevir trials (one conducted among treatment-naïve patients and one conducted among treatment-experienced patients)[@b5-tcrm-8-105],[@b11-tcrm-8-105] and one randomized placebo-controlled telaprevir trial (conducted among treatment-naïve patients)[@b8-tcrm-8-105] included data on sustained virologic response among compensated cirrhosis patients treated with a response-guided therapy duration. Relapse and discontinuation data were not available for compensated cirrhosis patients treated with a response-guided therapy duration.

[Tables L](#t20-tcrm-8-105){ref-type="table"} and [M in the Appendix](#t21-tcrm-8-105){ref-type="table"} show the results of the direct comparison between response-guided therapy regimens of telaprevir or boceprevir coadministered with peginterferon alpha plus ribavirin (intervention) and placebo coadministered with peginterferon alpha plus ribavirin (control) for patients with compensated cirrhosis. The results indicate that treatment-experienced patients with compensated cirrhosis provided with a response-guided therapy regimen that included boceprevir in combination with peginterferon alpha plus ribavirin are more likely to achieve a sustained virologic response when compared to those treated with peginterferon alpha plus ribavirin alone. No telaprevir trial included data on treatment-experienced compensated cirrhosis patients provided with a response-guided therapy regimen. No difference was observed between treatment-naïve compensated cirrhosis patients provided with a response-guided therapy regimen that included boceprevir or telaprevir in combination with peginterferon alpha plus ribavirin when compared to similar patients provided with peginterferon alpha plus ribavirin alone.

[Table N in the Appendix](#t22-tcrm-8-105){ref-type="table"} shows the results of the indirect comparison between response-guided therapy regimens of boceprevir coadministered with peginterferon alpha plus ribavirin and response-guided therapy regimens of telaprevir coadministered with peginterferon alpha plus ribavirin for patients with compensated cirrhosis. The results indicate that there are no differences between response-guided therapy regimens including boceprevir and telaprevir among treatment-naïve patients with compensated cirrhosis.

### Standard dose-durations of boceprevir or telaprevir among prior nonresponding and prior relapsing treatment-experienced patients

Both randomized placebo-controlled boceprevir trials conducted among experienced patients[@b11-tcrm-8-105],[@b12-tcrm-8-105] and one randomized placebo-controlled telaprevir trial conducted among experienced patients[@b14-tcrm-8-105] included sustained virologic response data stratified by prior nonresponding and prior relapsing patients for the standard-dose duration arms. Relapse and discontinuation data were not available for prior nonresponding and prior relapsing patients.

[Tables O](#t23-tcrm-8-105){ref-type="table"} and [P in the Appendix](#t24-tcrm-8-105){ref-type="table"} show the results of the direct comparison between standard-dose duration regimens of telaprevir or boceprevir coadministered with peginterferon alpha plus ribavirin (intervention) and placebo coadministered with peginterferon alpha plus ribavirin (control) for prior nonresponding and prior relapsing patients. The results indicate that, in general, both prior nonresponding and relapsing patients treated with a standard-dose duration regimen of boceprevir or telaprevir in combination with peginterferon alpha plus ribavirin are more likely to achieve a sustained virologic response when compared to those treated with peginterferon alpha plus ribavirin alone.

[Table Q in the Appendix](#t25-tcrm-8-105){ref-type="table"} shows the results of the indirect comparison between standard-dose duration regimens of boceprevir coadministered with peginterferon alpha plus ribavirin and standard-dose duration regimens of telaprevir coadministered with peginterferon alpha plus ribavirin for prior nonresponding and prior relapsing patients. The results show that there are no differences in terms of sustained virologic response between boceprevir and telaprevir for prior nonresponding and prior relapsing patients.

### Response-guided therapy durations that included boceprevir or telaprevir among prior nonresponding and prior relapsing treatment-experienced patients

One randomized placebo-controlled boceprevir trial conducted among experienced patients[@b11-tcrm-8-105] included sustained virologic response data stratified for prior relapsing patients for a response-guided therapy arm. Data on prior nonresponders was not available in this trial arm, nor was data on relapses and discontinuations. No telaprevir trial evaluated treatment-experienced patients treated with a response-guided therapy regimen.

[Table R in the Appendix](#t26-tcrm-8-105){ref-type="table"} shows the results of the direct comparison between response-guided therapy regimens of boceprevir coadministered with peginterferon alpha plus ribavirin (intervention) and placebo coadministered with peginterferon alpha plus ribavirin (control) for prior relapsing patients. The results indicate that prior relapsing patients treated with boceprevir in combination with peginterferon alpha plus ribavirin are generally more likely to achieve a sustained virologic response when compared to those treated with peginterferon alpha plus ribavirin alone.

Adverse events
--------------

### Adverse events among all patients treated with standard dose-duration boceprevir or telaprevir

All four randomized placebo-controlled boceprevir trials (two conducted among treatment-naïve patients and two conducted among treatment-experienced patients) that included standard-dose duration arms[@b5-tcrm-8-105],[@b6-tcrm-8-105],[@b11-tcrm-8-105],[@b12-tcrm-8-105] and three randomized placebo-controlled telaprevir trials (two conducted among treatment-naïve patients and one conducted among treatment-experienced patients) that included standard dose-duration arms[@b8-tcrm-8-105],[@b9-tcrm-8-105],[@b14-tcrm-8-105] provided adverse event data. [Tables S](#t27-tcrm-8-105){ref-type="table"} and [T in the Appendix](#t28-tcrm-8-105){ref-type="table"} show the results of the direct comparison between standard dose-duration regimens of telaprevir or boceprevir coadministered with peginterferon alpha plus ribavirin (intervention) and placebo coadministered with peginterferon alpha plus ribavirin (control).

[Table 7](#t7-tcrm-8-105){ref-type="table"} shows the results of the indirect comparison between standard-dose duration regimens of boceprevir coadministered with peginterferon alpha plus ribavirin and standard-dose duration regimens of telaprevir coadministered with peginterferon alpha plus ribavirin. The results indicate that naïve patients treated with a standard-dose duration regimen of telaprevir in combination with peginterferon alpha plus ribavirin are more likely to develop a rash when compared to those treated with a standard-dose duration regimen of boceprevir in combination with peginterferon alpha plus ribavirin. Furthermore, both naïve and experienced patients treated with a standard dose-duration regimen of telaprevir in combination with peginterferon alpha plus ribavirin are more likely to develop pruritus when compared to those treated with a standard dose-duration regimen of boceprevir in combination with peginterferon alpha plus ribavirin. No differences between boceprevir and telaprevir were observed for anemia and neutropenia.

### Adverse events among all patients treated with response-guided therapy durations that included boceprevir or telaprevir

Two randomized placebo-controlled boceprevir trials (one conducted among treatment-naïve patients and one conducted among treatment-experienced patients) that included response-guided therapy arms[@b5-tcrm-8-105],[@b11-tcrm-8-105] and one randomized placebo-controlled telaprevir trial (conducted among treatment-naïve patients) that included a response guided therapy arm[@b8-tcrm-8-105] provided adverse event data.

[Tables U](#t29-tcrm-8-105){ref-type="table"} and [V in the Appendix](#t30-tcrm-8-105){ref-type="table"} show the results of the direct comparison between response-guided therapy regimens of boceprevir or telaprevir coadministered with peginterferon alpha plus ribavirin (intervention) and placebo coadministered with peginterferon alpha plus ribavirin (control).

[Table 8](#t8-tcrm-8-105){ref-type="table"} shows the results of the indirect comparison between response-guided therapy regimens of boceprevir coadministered with peginterferon alpha plus ribavirin and response-guided therapy regimens of telaprevir coadministered with peginterferon alpha plus ribavirin. The results indicate that naïve patients treated with a response-guided therapy regimen that included boceprevir in combination with peginterferon alpha plus ribavirin are more likely to develop neutropenia when compared to those treated with a response-guided therapy regimen that included telaprevir in combination with peginterferon alpha plus ribavirin. Furthermore, naïve patients treated with a response-guided therapy regimen that included telaprevir in combination with peginterferon alpha plus ribavirin are more likely to develop rash or pruritus when compared to those treated with a response-guided therapy regimen that included boceprevir in combination with peginterferon alpha plus ribavirin. No differences were observed between boceprevir and telaprevir for anemia.

Discussion
==========

The results of the direct analysis indicate that patients provided a standard-dose duration or response-guided therapy duration of boceprevir or telaprevir in combination with peginterferon alpha plus ribavirin are generally more likely to achieve a sustained virologic response, less likely to relapse to treatment, and less likely to discontinue treatment when compared with those treated with peginterferon plus ribavirin alone. The results of the indirect analysis indicate that there are no significant differences between boceprevir and telaprevir in terms of sustained virologic response, relapse, or discontinuation of therapy for patients treated with standard-dose duration or response-guided therapy duration. These findings were consistent in both treatment-naïve and treatment-experienced study populations.

There are several issues to consider when interpreting the analysis. The authors are confident that all key studies were identified in the exhaustive search, and believe it unlikely that publication bias would exist in this high profile field. Good interobserver agreement was found between the included studies. The analysis used direct comparisons of telaprevir or boceprevir in combination with peginterferon alpha and ribavirin, as well as indirect comparisons of telaprevir and boceprevir in combination with peginterferon alpha and ribavirin. The validity of indirect comparisons has received extensive research.[@b37-tcrm-8-105]--[@b43-tcrm-8-105] However, it should be recognized that the strength of inference from indirect comparisons is limited by the inherent differences of the included studies.[@b19-tcrm-8-105] Some differences in the populations and methodology were found and addressed using meta-regression and subgroup analyses, as discussed further below. Additionally, where possible, the I^2^ statistic was obtained and showed that in most cases there was little variation between studies, although heterogeneity tests are poorly powered, further supporting the use of indirect comparisons.

In the absence of direct evidence, the indirect comparison method is widely accepted by agencies such as the United Kingdom National Institute for Health and Clinical Excellence, the Canadian Drug Safety and Effectiveness Network, and the United States Agency for Healthcare Research and Quality. The largest evaluation of the consistency between direct and indirect comparisons of trials, published in 2011, found that there was a statistically significant inconsistency in only 14% of evaluations.[@b40-tcrm-8-105] However, indirect comparisons may be underpowered to determine treatment differences, particularly when there is severe imbalance between the number of trials available for one treatment versus the other.[@b44-tcrm-8-105] The present study examined whether differences between treatments were significantly different in terms of a priori determined outcomes. The study did not determine whether the treatments were noninferior because noninferiority assumes that there is a reference drug.[@b45-tcrm-8-105] If the noninferiority margins were set as an upper CI of 0.8 and lower CI of 0.5 for sustained virologic response, then treatments appear to be noninferior.

There are certain trial level characteristics to consider. Telaprevir trials used a backbone therapy of predominantly peg-2a, while boceprevir trials used predominantly peg- 2b. Some studies have shown that peg-2a plus ribavirin is favorable over peg-2b plus ribavirin in terms of sustained virologic response.[@b46-tcrm-8-105],[@b21-tcrm-8-105] However, based on the results of the meta-regressions, this effect is minimal and should not have greatly influenced the outcomes in the present study. The weight-based ribavirin dosing strategy also differed between peg-2a and peg-2b; however, the level of detail necessary to control for this variable in the analysis was not available in the published literature.

The analysis of patients with compensated cirrhosis indicates that triple therapy including boceprevir or telaprevir is generally advantageous to conventional peginterferon alpha and ribavirin therapy in terms of sustained virologic response. However, the number of patients with compensated cirrhosis in the included studies was small, and the data reported on this subgroup were limited. Therefore, drawing concrete conclusions regarding this treatment subgroup should be cautioned.

The analysis utilized the available data for treatment-experienced patients, as presented in the trial publications, to examine sustained virologic response, relapse, and treatment discontinuation. A priori, it was known that most trials also presented separate data for prior relapsing and prior nonresponding treatment-experienced patients; and therefore, it was also possible to conduct analyses for these subgroups. However, there is a major limitation to this approach. The term nonresponder is typically used to refer to the combination of partial responders and null responders. However, the boceprevir trials, conducted among treatment-experienced patients, did not recruit null responders. In this regard, the treatment populations are dissimilar between the boceprevir and telaprevir trials, and the results of the analysis may underestimate the efficacy of telaprevir and/or overestimate the efficacy of boceprevir in the prior nonresponse subgroup of patients. In spite of this, in nontrial clinical practice, the history of prior on-treatment virologic response to treatment is often incomplete or missing altogether. Therefore, composite estimates for treatment-experienced patients, as provided by the present analysis, may be of clinical utility.

The analysis of adverse events indicated that skin conditions, such as rash and pruritus were more common in those treated with boceprevir or telaprevir in combination with peginterferon alpha plus ribavirin than peginterferon alpha plus ribavirin alone. The indirect analysis indicates that these conditions were more likely to occur with those taking telaprevir than boceprevir. The primary concern related to the dermatological complications of telaprevir is that of severe rash, and in rare cases, Stevens--Johnson syndrome.[@b47-tcrm-8-105]

Cytopenias are a well-recognized side effect of peginterferon alpha and ribavirin therapy. The analysis showed that both boceprevir and telaprevir generally appear to exacerbate such conditions. Indirect analyses comparing boceprevir and telaprevir found that neutropenia is more likely to occur in boceprevir recipients provided with a response-guided therapy regimen. However, there is little, if any, clinical consequence with treatment-induced neutropenia in terms of infectious diseases complication risk.[@b48-tcrm-8-105]

In conclusion, no significant differences were found between the two direct-acting agents in terms of major clinical endpoints. Adverse event profiles differ between agents and are key variables that clinicians and patients will consider when selecting a protease inhibitor. Recognizing that indirect estimates are best estimates in the absence of direct (head-to-head) evaluations, the authors believe that the present study has implications for clinicians in terms of choosing the most effective and most tolerable direct-acting agent.
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###### 

Direct comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, or discontinuing treatment in the trial intervention (response-guided therapy duration boceprevir) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin)

  Trial                              Intervention   Control          Relative risk (95% CI)                    
  ---------------------------------- -------------- ---------------- ------------------------ ---------------- -------------------
  **Sustained virologic response**                                                                             
  Naïve patients                                                                                               
   Poordad et al[@b5-tcrm-8-105]     233/368        63% (60%--67%)   137/363                  38% (34%--41%)   1.69 (1.44--1.96)
  Experienced patients                                                                                         
   Bacon et al[@b11-tcrm-8-105]      95/162         59% (53%--64%)   17/80                    22% (16%--28%)   2.76 (1.81--4.35)
  **Relapse**                                                                                                  
  Naïve patients                                                                                               
   Poordad et al[@b5-tcrm-8-105]     24/257         9% (7%--12%)     39/176                   22% (18%--27%)   0.42 (0.30--0.59)
  Experienced patients                                                                                         
   Bacon et al[@b11-tcrm-8-105]      17/111         16% (11%--21%)   8/25                     33% (21%--46%)   0.48 (0.29--0.80)
  **Discontinuation**                                                                                          
  Naïve patients                                                                                               
   Poordad et al[@b5-tcrm-8-105]     139/368        38% (34%--41%)   204/363                  56% (53%--60%)   0.67 (0.60--0.75)
  Experienced patients                                                                                         
   Bacon et al[@b11-tcrm-8-105]      52/162         32% (27%--37%)   55/80                    69% (61%--75%)   0.47 (0.39--0.56)

**Abbreviation:** CI, confidence interval.

###### 

Direct comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, or discontinuing treatment in the trial intervention (response-guided therapy duration telaprevir) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin)

  Trial                              Intervention   Control          Relative risk (95% CI)                    
  ---------------------------------- -------------- ---------------- ------------------------ ---------------- -------------------
  **Sustained virologic response**                                                                             
  Naïve patients                                                                                               
   Jacobson et al[@b8-tcrm-8-105]    271/363        72% (66%--77%)   158/361                  44% (40%--47%)   1.71 (1.50--1.95)
                                     250/364                                                                   
  **Relapse**                                                                                                  
  Naïve patients                                                                                               
   Jacobson et al[@b8-tcrm-8-105]    27/314         9% (7%--12%)     64/229                   28% (24%--32%)   0.32 (0.24--0.43)
                                     28/295                                                                    
  **Discontinuation**                                                                                          
  Naïve patients                                                                                               
   Jacobson et al[@b8-tcrm-8-105]    95/363         27% (24%--31%)   159/361                  44% (40%--48%)   0.62 (0.54--0.72)
                                     104/364                                                                   

**Abbreviation:** CI, confidence interval.

###### 

Direct comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, or discontinuing treatment in the trial intervention (boceprevir provided at a dose of 800 mg three times per day at any point during a 48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks)

  Trial                              Intervention   Control          Relative risk (95% CI) (I^2^ \[95% CI\])                    
  ---------------------------------- -------------- ---------------- ------------------------------------------ ---------------- -----------------------------------------
  **Sustained virologic response**                                                                                               
  Naïve patients                                                                                                                 
   Kwo et al[@b6-tcrm-8-105]         77/103         62% (53%--69%)   39/104                                     38% (33%--42%)   1.65 (1.43--1.91) (48.1% \[0%--77.7%\])
                                     69/103                                                                                      
                                     8/16                                                                                        
                                     21/59                                                                                       
   Poordad et al[@b5-tcrm-8-105]     242/366        137/363                                                                      
                                     233/368                                                                                     
  Experienced patients                                                                                                           
   Bacon et al[@b11-tcrm-8-105]      107/161        63% (58%--68%)   17/80                                      21% (15%--28%)   2.98 (2.29--3.87) (0% \[0%--72.9%\])
                                     95/162                                                                                      
   Flamm et al[@b12-tcrm-8-105]      86/134         14/67                                                                        
  **Relapse**                                                                                                                    
  Naïve patients                                                                                                                 
   Kwo et al[@b6-tcrm-8-105]         2/81           9% (6%--12%)     12/53                                      23% (17%--28%)   0.42 (0.28--0.61) (31.7% \[0%--72.2%\])
                                     5/76                                                                                        
                                     1/9                                                                                         
                                     6/28                                                                                        
   Poordad et al[@b5-tcrm-8-105]     24/265         39/176                                                                       
                                     24/257                                                                                      
  Experienced patients                                                                                                           
   Bacon et al[@b11-tcrm-8-105]      14/121         13% (10%--17%)   8/25                                       33% (21%--47%)   0.40 (0.26--0.62) (0% \[0%--72.9%\])
                                     17/111                                                                                      
   Flamm et al[@b12-tcrm-8-105]      11/95          7/21                                                                         
  **Discontinuation**                                                                                                            
  Naïve patients                                                                                                                 
   Kwo et al[@b6-tcrm-8-105]         27/103         39% (34%--45%)   52/104                                     54% (49%--60%)   0.75 (0.64--0.88) (54.1% \[0%--79.7%\])
                                     40/103                                                                                      
                                     8/16                                                                                        
                                     31/59                                                                                       
   Poordad et al[@b5-tcrm-8-105]     151/366        204/363                                                                      
                                     139/368                                                                                     
  Experienced patients                                                                                                           
   Bacon et al[@b11-tcrm-8-105]      55/161         36% (31%--41%)   55/80                                      69% (61%--76%)   0.52 (0.44--0.60) (0% \[0%--72.8%\])
                                     52/162                                                                                      
   Flamm et al[@b12-tcrm-8-105]      55/134         47/67                                                                        

**Abbreviation:** CI, confidence interval.

###### 

Direct comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, or discontinuing treatment in the trial intervention (telaprevir provided at a dose of 750 mg three times per day at any point during a 48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks)

  Trial                                 Intervention   Control          Relative risk (95% CI) (I^2^ \[95% CI\])                    
  ------------------------------------- -------------- ---------------- ------------------------------------------ ---------------- --------------------------------------------
  **Sustained virologic response**                                                                                                  
  Naïve patients                                                                                                                    
   Jacobson et al[@b8-tcrm-8-105]       271/363        71% (66%--75%)   158/361                                    43% (39%--48%)   1.64 (1.50--1.79) (0% \[0%--72.9%\])
                                        250/364                                                                                     
   McHutchison et al[@b9-tcrm-8-105]    53/79          31/75                                                                        
  Experienced patients                                                                                                              
   Zeuzem et al[@b14-tcrm-8-105]        171/266        62% (55%--69%)   22/132                                     16% (11%--20%)   3.88 (3.05--4.94) (0% \[0%--72.9%\])
                                        175/264                                                                                     
   McHutchison et al[@b13-tcrm-8-105]   60/113         16/114                                                                       
  **Relapse**                                                                                                                       
  Naïve patients                                                                                                                    
   Jacobson et al[@b8-tcrm-8-105]       27/314         9% (7%--11%)     64/229                                     29% (24%--35%)   0.30 (0.22--0.39) (0% \[0%--72.9%\])
                                        28/295                                                                                      
   McHutchison et al[@b9-tcrm-8-105]    3/51           8/35                                                                         
  Experienced patients                                                                                                              
   Zeuzem et al[@b14-tcrm-8-105]        27/210         13% (10%--16%)   33/55                                      58% (50%--66%)   0.22 (0.17--0.29) (0% \[0%--72.9%\])
                                        26/204                                                                                      
   McHutchison et al[@b13-tcrm-8-105]   10/76          18/34                                                                        
  **Discontinuation**                                                                                                               
  Naïve patients                                                                                                                    
   Jacobson et al[@b8-tcrm-8-105]       80/363         27% (21%--32%)   159/361                                    34% (15%--55%)   0.75 (0.45--1.23) (84.3% \[15.5%--93.0%\])
                                        104/364                                                                                     
   McHutchison et al[@b9-tcrm-8-105]    25/79          17/75                                                                        
  Experienced patients                                                                                                              
   Zeuzem et al[@b14-tcrm-8-105]        100/266        39% (29%--50%)   82/132                                     65% (59%--71%)   0.60 (0.47--0.77) (73.7% \[0%--90.0%\])
                                        79/264                                                                                      
   McHutchison et al[@b13-tcrm-8-105]   58/113         78/114                                                                       

**Abbreviations:** CI, confidence interval.

###### 

Direct comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, or discontinuing treatment in the trial intervention (boceprevir provided at a dose of 800 mg three times per day at any point during a 12--48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks)

  Trial                              Intervention   Control          Relative risk (95% CI) (I^2^ \[95% CI\])                    
  ---------------------------------- -------------- ---------------- ------------------------------------------ ---------------- -------------------------------------------
  **Sustained virologic response**                                                                                               
  Naïve patients                                                                                                                 
   Kwo et al[@b6-tcrm-8-105]         77/103         60% (53%--67%)   39/104                                     38% (33%--42%)   1.62 (1.45--1.82) (36.6% \[0%--70.8%\])
                                     69/103                                                                                      
                                     8/16                                                                                        
                                     21/59                                                                                       
                                     58/103                                                                                      
                                     58/107                                                                                      
   Poordad et al[@b5-tcrm-8-105]     242/366        137/363                                                                      
                                     233/368                                                                                     
  **Relapse**                                                                                                                    
  Naïve patients                                                                                                                 
   Kwo et al[@b6-tcrm-8-105]         2/81           13% (8%--20%)    12/53                                      23% (17%--28%)   0.55 (0.35--0.88) (67.5% \[9.6%--82.8%\])
                                     5/76                                                                                        
                                     1/9                                                                                         
                                     6/28                                                                                        
                                     18/79                                                                                       
                                     24/84                                                                                       
   Poordad et al[@b5-tcrm-8-105]     24/265         39/176                                                                       
                                     24/257                                                                                      
  **Discontinuation**                                                                                                            
  Naïve patients                                                                                                                 
   Kwo et al[@b6-tcrm-8-105]         27/103         36% (31%--42%)   52/104                                     54% (49%--60%)   0.70 (0.61--0.82) (54.9% \[0%--77.8%\])
                                     40/103                                                                                      
                                     8/16                                                                                        
                                     31/59                                                                                       
                                     27/103                                                                                      
                                     30/107                                                                                      
   Poordad et al[@b5-tcrm-8-105]     151/366        204/363                                                                      
                                     139/368                                                                                     

**Abbreviation:** CI, confidence interval.

###### 

Direct comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, or discontinuing treatment in the trial intervention (telaprevir provided at a dose of 750 mg three times per day at any point during a 12--48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks)

  Trial                                 Intervention   Control          Relative risk (95% CI) (I^2^ \[95% CI\])                    
  ------------------------------------- -------------- ---------------- ------------------------------------------ ---------------- --------------------------------------------
  **Sustained virologic response**                                                                                                  
  Naïve patients                                                                                                                    
   Jacobson et al[@b8-tcrm-8-105]       271/363        67% (62%--72%)   158/361                                    44% (41%--47%)   1.57 (1.45--1.69) (0% \[0%--56.3%\])
                                        250/364                                                                                     
   McHutchison et al[@b9-tcrm-8-105]    53/79          31/75                                                                        
                                        48/79                                                                                       
                                        6/17                                                                                        
   Hezode et al[@b7-tcrm-8-105]         49/82          38/82                                                                        
                                        56/81                                                                                       
   Kumada et al[@b10-tcrm-8-105]        92/126         31/63                                                                        
  Experienced patients                                                                                                              
   Zeuzem et al[@b14-tcrm-8-105]        171/266        60% (52%--67%)   22/132                                     16% (11%--20%)   3.84 (3.09--4.76) (0% \[0%--67.9%\])
                                        175/264                                                                                     
   McHutchison et al[@b13-tcrm-8-105]   60/113         16/114                                                                       
                                        59/115                                                                                      
  **Relapse**                                                                                                                       
  Naïve patients                                                                                                                    
   Jacobson et al[@b8-tcrm-8-105]       27/314         13% (8%--18%)    64/229                                     26% (22%--31%)   0.53 (0.32--0.88) (73% \[31.9%--85.1%\])
                                        28/295                                                                                      
   McHutchison et al[@b9-tcrm-8-105]    3/51           8/35                                                                         
                                        1/41                                                                                        
                                        3/9                                                                                         
   Hezode et al[@b7-tcrm-8-105]         19/63          10/45                                                                        
                                        8/57                                                                                        
   Kumada et al[@b10-tcrm-8-105]        20/117         11/49                                                                        
  Experienced patients                                                                                                              
   Zeuzem et al[@b14-tcrm-8-105]        27/210         17% (10%--24%)   33/55                                      57% (50%--64%)   0.28 (0.17--0.46) (76.3% \[0%--89.4%\])
                                        26/204                                                                                      
   McHutchison et al[@b13-tcrm-8-105]   10/76          18/34                                                                        
                                        26/87                                                                                       
  **Discontinuation**                                                                                                               
  Naïve patients                                                                                                                    
   Jacobson et al[@b8-tcrm-8-105]       95/363         28% (22%--34%)   159/361                                    33% (27%--40%)   0.86 (0.61--1.22) (84.8% \[69.9%--90.5%\])
                                        104/364                                                                                     
   McHutchison et al[@b9-tcrm-8-105]    25/79          17/75                                                                        
                                        37/79                                                                                       
                                        8/17                                                                                        
   Hezode et al[@b7-tcrm-8-105]         10/82          32/82                                                                        
                                        20/81                                                                                       
   Kumada et al[@b10-tcrm-8-105]        27/126         17/63                                                                        
  Experienced patients                                                                                                              
   Zeuzem et al[@b14-tcrm-8-105]        100/266        36% (27%--45%)   82/132                                     65% (59%--71%)   0.54 (0.41--0.71) (80.4% \[19.7%--90.7%\])
                                        79/264                                                                                      
   McHutchison et al[@b13-tcrm-8-105]   58/113         78/114                                                                       
                                        29/115                                                                                      

**Abbreviation:** CI, confidence interval.

###### 

Adjusted indirect comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, or discontinuing treatment at any point in a 48-week treatment course using boceprevir or telaprevir

                                     Boceprevir          Telaprevir          Relative risk (95% CI)   *P* value
  ---------------------------------- ------------------- ------------------- ------------------------ -----------
  **Sustained virologic response**                                                                    
  Patients                                                                                            
   Naïve                             1.65 (1.43--1.91)   1.64 (1.50--1.79)   1.01 (0.85--1.19)        0.94
   Experienced                       2.98 (2.29--3.87)   3.88 (3.05--4.94)   0.77 (0.54--1.10)        0.15
  **Relapse**                                                                                         
  Patients                                                                                            
   Naïve                             0.42 (0.28--0.61)   0.30 (0.22--0.39)   1.40 (0.86--2.28)        0.18
   Experienced                       0.40 (0.26--0.62)   0.22 (0.17--0.29)   1.82 (1.09--3.03)        0.02
  **Discontinuation**                                                                                 
  Patients                                                                                            
   Naïve                             0.75 (0.64--0.88)   0.75 (0.45--1.23)   1.00 (0.59--1.69)        1.00
   Experienced                       0.52 (0.44--0.60)   0.60 (0.47--0.77)   0.87 (0.65--1.16)        0.34

**Abbreviation:** CI, confidence interval.

###### 

Adjusted indirect comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, or discontinuing treatment at any point in a 12--48-week treatment course using boceprevir or telaprevir

                                     Boceprevir          Telaprevir          Relative risk (95% CI)   *P* value
  ---------------------------------- ------------------- ------------------- ------------------------ -----------
  **Sustained virologic response**                                                                    
  Patients                                                                                            
   Naïve                             1.62 (1.45--1.82)   1.57 (1.45--1.69)   1.06 (0.92--1.21)        0.41
   Experienced                       2.98 (2.29--3.87)   3.84 (3.09--4.76)   0.78 (0.55--1.09)        0.14
  **Relapse**                                                                                         
  Patients                                                                                            
   Naïve                             0.55 (0.35--0.88)   0.53 (0.32--0.88)   1.04 (0.52--2.06)        0.91
   Experienced                       0.40 (0.26--0.62)   0.28 (0.17--0.46)   1.43 (0.74--2.77)        0.29
  **Discontinuation**                                                                                 
  Patients                                                                                            
   Naïve                             0.70 (0.61--0.82)   0.86 (0.61--1.22)   0.81 (0.56--1.19)        0.28
   Experienced                       0.52 (0.44--0.60)   0.54 (0.41--0.71)   0.96 (0.70--1.32)        0.81

**Abbreviation:** CI, confidence interval.

###### 

Direct comparison of the proportion of patients achieving sustained virologic response in the trial intervention (boceprevir provided at a dose of 800 mg three times per day during weeks 4--48 of a 48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks) among patients with compensated cirrhosis

  Trial                              Intervention   Control          Relative risk (95% CI)                    
  ---------------------------------- -------------- ---------------- ------------------------ ---------------- --------------------
  **Sustained virologic response**                                                                             
  Naïve patients                                                                                               
   Kwo et al[@b6-tcrm-8-105]         3/6            44% (27%--61%)   2/8                      39% (20%--59%)   1.07 (0.55--2.09)
   Poordad et al[@b5-tcrm-8-105]     10/24          6/13                                                       
  Experienced patients                                                                                         
   Bacon et al[@b11-tcrm-8-105]      17/22          63% (37%--86%)   0/10                     5% (0.1%--7%)    6.91 (1.46--32.61)
   Flamm et al[@b12-tcrm-8-105]      12/24          1/9                                                        

**Abbreviation:** CI, confidence interval.

###### 

Direct comparison of the proportion of patients achieving sustained virologic response in the trial intervention (telaprevir provided at a dose of 750 mg three times per day during weeks 1--12 of a 48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks) among patients with compensated cirrhosis

  Trial                              Intervention   Control          Relative risk (95% CI)                    
  ---------------------------------- -------------- ---------------- ------------------------ ---------------- --------------------
  **Sustained virologic response**                                                                             
  Naïve patients                                                                                               
   Jacobson et al[@b8-tcrm-8-105]    13/21          61% (47%--75%)   7/21                     34% (21%--49%)   1.86 (1.14--3.03)
  Experienced patients                                                                                         
   Zeuzem et al[@b14-tcrm-8-105]     77/119         65% (58%--71%)   6/59                     11% (6%--17%)    6.36 (3.69--10.97)

**Abbreviation:** CI, confidence interval.

###### 

Adjusted indirect comparison of the proportion of compensated cirrhosis patients achieving a sustained virologic response in the boceprevir and telaprevir standard-dose durations

  Patients                           Boceprevir           Telaprevir           Relative risk (95% CI)   *P* value
  ---------------------------------- -------------------- -------------------- ------------------------ -----------
  **Sustained virologic response**                                                                      
  Naïve                              1.07 (0.55--2.09)    1.86 (1.14--3.03)    1.73 (0.70--4.28)        0.33
  Experienced                        6.91 (1.46--32.61)   5.84 (3.25--10.50)   0.84 (0.16--4.44)        0.36

**Abbreviation:** CI, confidence interval.

###### 

Direct comparison of the proportion of patients achieving sustained virologic response in the trial intervention (response-guided therapy duration boceprevir) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin) among patients with compensated cirrhosis

  Trial                              Intervention   Control          Relative risk (95% CI)                    
  ---------------------------------- -------------- ---------------- ------------------------ ---------------- --------------------
  **Sustained virologic response**                                                                             
  Naïve patients                                                                                               
   Poordad et al[@b5-tcrm-8-105]     5/16           31% (11%--59%)   6/13                     46% (19%--75%)   0.68 (0.27--1.70)
  Experienced patients                                                                                         
   Bacon et al[@b11-tcrm-8-105]      6/17           35% (14%--62%)   0/10                     0%               7.41 (1.04--52.94)

**Abbreviation:** CI, confidence interval.

###### 

Direct comparison of the proportion of patients achieving sustained virologic response in the trial intervention (response-guided therapy duration telaprevir) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin) among patients with compensated cirrhosis

  Trial                              Intervention   Control          Relative risk (95% CI)                    
  ---------------------------------- -------------- ---------------- ------------------------ ---------------- -------------------
  **Sustained virologic response**                                                                             
  Naïve patients                                                                                               
   Jacobson et al[@b8-tcrm-8-105]    13/21          51% (33%--69%)   7/21                     33% (15%--57%)   1.56 (0.94--2.60)
                                     11/26                                                                     

**Abbreviation:** CI, confidence interval.

###### 

Adjusted indirect comparison of the proportion of compensated cirrhosis patients achieving a sustained virologic response in the boceprevir and telaprevir response-guided therapy durations

  Patients                           Boceprevir           Telaprevir          Relative risk (95% CI)   *P* value
  ---------------------------------- -------------------- ------------------- ------------------------ -----------
  **Sustained virologic response**                                                                     
  Naïve                              0.68 (0.27--1.70)    1.56 (0.94--2.60)   0.44 (0.15--1.25)        0.12
  Experienced                        7.41 (1.04--52.94)   --                  --                       --

**Abbreviation:** CI, confidence interval.

###### 

Direct comparison of the proportion of patients achieving sustained virologic response in the trial intervention (boceprevir provided at a dose of 800 mg three times per day during weeks 4--48 of a 48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks) among prior nonresponding and relapsing treatment-experienced patients

  Trial                              Intervention   Control          Relative risk (95% CI)                    
  ---------------------------------- -------------- ---------------- ------------------------ ---------------- --------------------
  **Sustained virologic response**                                                                             
  Prior nonresponders                                                                                          
   Bacon et al[@b11-tcrm-8-105]      30/58          50% (40%--60%)   2/29                     8% (2%--17%)     8.09 (2.66--24.65)
   Flamm et al[@b12-tcrm-8-105]      17/36          1/20                                                       
  Prior relapsers                                                                                              
   Bacon et al[@b11-tcrm-8-105]      77/103         72% (66%--78%)   15/51                    29% (21%--38%)   2.54 (1.84--3.52)
   Flamm et al[@b12-tcrm-8-105]      69/98          13/47                                                      

**Abbreviation:** CI, confidence interval.

###### 

Direct comparison of the proportion of patients achieving sustained virologic response in the trial intervention (telaprevir provided at a dose of 800 mg three times per day during weeks 1--12 of a 48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks) among prior nonresponding and relapsing treatment-experienced patients

  Trial                              Intervention   Control          Relative risk (95% CI)                    
  ---------------------------------- -------------- ---------------- ------------------------ ---------------- -------------------
  **Sustained virologic response**                                                                             
  Prior nonresponders                                                                                          
   Zeuzem et al[@b14-tcrm-8-105]     50/121         41% (35%--48%)   6/64                     10% (5%--16%)    4.41 (2.52--7.71)
  Prior relapsers                                                                                              
   Zeuzem et al[@b14-tcrm-8-105]     121/145        83% (79%--87%)   16/68                    24% (17%--31%)   3.55 (2.61--4.82)

**Abbreviation:** CI, confidence interval.

###### 

Adjusted indirect comparison of the proportion of prior nonresponding and prior relapsing patients achieving a sustained virologic response in the boceprevir and telaprevir standard-dose durations

  Patients                           Boceprevir           Telaprevir          Relative risk (95% CI)   *P* value
  ---------------------------------- -------------------- ------------------- ------------------------ -----------
  **Sustained virologic response**                                                                     
  Prior nonresponders                8.09 (2.66--24.65)   4.41 (2.52--7.71)   0.54 (0.15--1.89)        0.33
  Prior relapsers                    2.54 (1.84--3.52)    3.55 (2.61--4.82)   0.71 (0.45--1.11)        0.14

**Abbreviation:** CI, confidence interval.

###### 

Direct comparison of the proportion of patients achieving sustained virologic response in the response guided therapy trial intervention (response-guided boceprevir) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks) among prior relapsing treatment-experienced patients

  Trial                              Intervention   Control          Relative risk (95% CI)                  
  ---------------------------------- -------------- ---------------- ------------------------ -------------- --------------------
  **Sustained virologic response**                                                                           
  Prior relapsers                                                                                            
   Bacon et al[@b11-tcrm-8-105]      23/57          40% (28%--54%)   2/29                     7% (0%--23%)   5.85 (1.75--21.71)

**Abbreviation:** CI, confidence interval.

###### 

Direct comparison of adverse events between the trial intervention (boceprevir provided at a dose of 800 mg three times per day during weeks 4--48 of a 48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks)

  Trial                            Intervention   Control          Relative risk (95% CI)                    
  -------------------------------- -------------- ---------------- ------------------------ ---------------- -------------------
  **Anemia**                                                                                                 
  Naïve patients                                                                                             
   Kwo et al[@b6-tcrm-8-105]       54/103         50% (45%--54%)   35/104                   30% (26%--35%)   1.63 (1.39--1.92)
   Poordad et al[@b5-tcrm-8-105]   179/366        107/363                                                    
  Experienced patients                                                                                       
   Bacon et al[@b11-tcrm-8-105]    74/161         42% (34%--50%)   16/80                    34% (10%--64%)   1.30 (0.42--4.03)
   Flamm et al[@b12-tcrm-8-105]    50/134         33/67                                                      
  **Neutropenia**                                                                                            
  Naïve patients                                                                                             
   Kwo et al[@b6-tcrm-8-105]       26/103         25% (22%--30%)   12/104                   17% (9%--27%)    1.51 (0.85--2.68)
   Poordad et al[@b5-tcrm-8-105]   93/366         77/363                                                     
  Experienced patients                                                                                       
   Flamm et al[@b12-tcrm-8-105]    31/134         23% (18%--29%)   18/67                    27% (20%--35%)   0.86 (0.60--1.23)
  **Rash**                                                                                                   
  Naïve patients                                                                                             
   Poordad et al[@b5-tcrm-8-105]   88/366         24% (21%--27%)   83/363                   23% (20%--26%)   1.05 (0.87--1.27)
  Experienced patients                                                                                       
   Bacon et al[@b11-tcrm-8-105]    22/161         15% (12%--20%)   4/80                     8% (3%--14%)     1.99 (1.06--3.72)
   Flamm et al[@b12-tcrm-8-105]    23/134         7/67                                                       
  **Pruritus**                                                                                               
  Naïve patients                                                                                             
   Poordad et al[@b5-tcrm-8-105]   94/366         26% (23%--29%)   98/363                   27% (24%--30%)   0.95 (0.80--1.13)
  Experienced patients                                                                                       
   Bacon et al[@b11-tcrm-8-105]    31/161         19% (15%--24%)   14/80                    18% (12%--24%)   1.10 (0.73--1.65)

**Abbreviation:** CI, confidence interval.

###### 

Direct comparison of adverse events between the trial intervention (telaprevir provided at a dose of 750 mg three times per day during weeks 1--12 of a 48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks)

  Trial                                Intervention   Control          Relative risk (95% CI)                    
  ------------------------------------ -------------- ---------------- ------------------------ ---------------- -------------------
  **Anemia**                                                                                                     
  Naïve patients                                                                                                 
   Jacobson et al[@b8-tcrm-8-105]      135/363        35% (28%--42%)   70/361                   22% (15%--29%)   1.51 (0.88--2.61)
   McHutchison et al[@b9-tcrm-8-105]   23/79          20/75                                                      
  Experienced patients                                                                                           
   Zeuzem et al[@b14-tcrm-8-105]       79/266         30% (26%--34%)   20/132                   15% (11%--20%)   1.96 (1.43--2.68)
  **Neutropenia**                                                                                                
  Naïve patients                                                                                                 
   Jacobson et al[@b8-tcrm-8-105]      51/363         18% (10%--29%)   68/361                   20% (16%--24%)   0.81 (0.54--1.04)
   McHutchison et al[@b9-tcrm-8-105]   19/79          18/75                                                      
  Experienced patients                                                                                           
   Zeuzem et al[@b14-tcrm-8-105]       38/266         14% (12%--18%)   14/132                   11% (7%--15%)    1.35 (0.90--2.02)
  **Rash**                                                                                                       
  Naïve patients                                                                                                 
   Jacobson et al[@b8-tcrm-8-105]      133/363        48% (26%--71%)   88/361                   32% (17%--49%)   1.49 (1.24--1.80)
   McHutchison et al[@b9-tcrm-8-105]   48/79          31/75                                                      
  Experienced patients                                                                                           
   Zeuzem et al[@b14-tcrm-8-105]       99/266         37% (33%--41%)   25/132                   19% (15%--24%)   1.97 (1.50--2.58)
  **Pruritus**                                                                                                   
  Naïve patients                                                                                                 
   Jacobson et al[@b8-tcrm-8-105]      181/363        47% (38%--55%)   131/361                  30% (18%--44%)   1.41 (1.20--1.66)
   McHutchison et al[@b9-tcrm-8-105]   32/79          17/75                                                      
  Experienced patients                                                                                           
   Zeuzem et al[@b14-tcrm-8-105]       138/266        52% (48%--56%)   36/132                   27% (22%--33%)   1.90 (1.54--2.35)

**Abbreviation:** CI, confidence interval.

###### 

Direct comparison of adverse events between the trial intervention (response-guided therapy duration boceprevir) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin)

  Trial                            Intervention   Control          Relative risk (95% CI)                    
  -------------------------------- -------------- ---------------- ------------------------ ---------------- -------------------
  **Anemia**                                                                                                 
  Naïve patients                                                                                             
   Poordad et al[@b5-tcrm-8-105]   182/368        49% (46%--53%)   107/363                  30% (26%--33%)   1.68 (1.47--1.92)
  Experienced patients                                                                                       
   Bacon et al[@b11-tcrm-8-105]    70/162         43% (38%--49%)   16/80                    20% (15%--27%)   2.16 (1.55--3.02)
  **Neutropenia**                                                                                            
  Naïve patients                                                                                             
   Poordad et al[@b5-tcrm-8-105]   92/368         25% (22%--28%)   77/363                   21% (18%--24%)   1.18 (0.98--1.42)
  **Rash**                                                                                                   
  Naïve patients                                                                                             
   Poordad et al[@b5-tcrm-8-105]   93/368         25% (22%--29%)   83/363                   23% (20%--26%)   1.11 (0.92--1.33)
  Experienced patients                                                                                       
   Bacon et al[@b11-tcrm-8-105]    27/162         17% (13%--21%)   4/80                     6% (3%--10%)     3.33 (1.63--6.83)
  **Pruritus**                                                                                               
  Naïve patients                                                                                             
   Poordad et al[@b5-tcrm-8-105]   87/368         24% (21%--27%)   98/363                   27% (24%--30%)   0.88 (0.73--1.04)
  Experienced patients                                                                                       
   Bacon et al[@b11-tcrm-8-105]    30/162         19% (15%--23%)   14/80                    18% (12%--24%)   1.06 (0.70--1.59)

**Abbreviation:** CI, confidence interval.

###### 

Direct comparison of adverse events between the trial intervention (response-guided therapy duration telaprevir) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin)

  Trial                             Intervention   Control          Relative risk (95% CI)                    
  --------------------------------- -------------- ---------------- ------------------------ ---------------- -------------------
  **Anemia**                                                                                                  
  Naïve patients                                                                                              
   Jacobson et al[@b8-tcrm-8-105]   135/363        38% (35%--42%)   70/361                   19% (17%--22%)   1.96 (1.64--2.33)
                                    141/364                                                                   
  **Neutropenia**                                                                                             
  Naïve patients                                                                                              
   Jacobson et al[@b8-tcrm-8-105]   51/363         16% (13%--19%)   69/361                   19% (16%--22%)   0.81 (0.65--1.02)
                                    62/364                                                                    
  **Rash**                                                                                                    
  Naïve patients                                                                                              
   Jacobson et al[@b8-tcrm-8-105]   133/363        36% (33%--40%)   88/361                   24% (21%--28%)   1.48 (1.26--1.74)
                                    129/364                                                                   
  **Pruritus**                                                                                                
  Naïve patients                                                                                              
   Jacobson et al[@b8-tcrm-8-105]   181/363        48% (43%--52%)   131/361                  36% (33%--40%)   1.31 (1.16--1.48)
                                    165/364                                                                   

**Abbreviation:** CI, confidence interval.
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###### 

Study characteristics of the boceprevir trials

  Trial                           Region                     Treatment experience   Arm            No of patients   Age in years (mean)   Male sex -- no (%)   HCV genotype 1a -- no (%)   HCV genotype 1b -- no (%)   Total treatment duration   Boceprevir treatment duration   Boceprevir dose      Pegylated interferon alpha dose   Ribavirin dose
  ------------------------------- -------------------------- ---------------------- -------------- ---------------- --------------------- -------------------- --------------------------- --------------------------- -------------------------- ------------------------------- -------------------- --------------------------------- -------------------
  Kwo et al[@b6-tcrm-8-105]       North America and Europe   Naïve                  Intervention   103              48                    51 (50)              53 (51)                     37 (36)                     28 weeks                   Weeks 4--28                     800 mg 3 times/day   Alpha-2b; 1.5 ug/kg/week          800--1400 mg/day
  Intervention                    107                        46                     63 (59)        67 (63)          30 (28)               28 weeks             Weeks 0--28                 800 mg 3 times/day          Alpha-2b; 1.5 ug/kg/week   800--1400 mg/day                                                                       
  Intervention                    103                        48                     58 (56)        60 (58)          35 (34)               48 weeks             Weeks 4--48                 800 mg 3 times/day          Alpha-2b; 1.5 ug/kg/week   800--1400 mg/day                                                                       
  Intervention                    103                        47                     63 (61)        55 (53)          36 (35)               48 weeks             Weeks 0--48                 800 mg 3 times/day          Alpha-2b; 1.5 ug/kg/week   800--1400 mg/day                                                                       
  Intervention                    16                         50                     9 (56)         7 (44)           7 (44)                48 weeks             Weeks 0--48                 800 mg 3 times/day          Alpha-2b; 1.5 ug/kg/week   800--1400 mg/day                                                                       
  Intervention                    59                         49                     41 (69)        39 (66)          18 (31)               48 weeks             Weeks 0--48                 800 mg 3 times/day          Alpha-2b; 1.5 ug/kg/week   400--1000 mg/day                                                                       
  Control                         104                        48                     70 (67)        53 (51)          42 (40)               48 weeks             --                          --                          Alpha-2b; 1.5 ug/kg/week   800--1400 mg/day                                                                       
  Poordad et al[@b5-tcrm-8-105]   North America and Europe   Naïve                  Intervention   368              50                    229 (62)             234 (64)                    124 (34)                    48 weeks                   Weeks 4--28                     800 mg 3 times/day   Alpha-2b; 1.5 ug/kg/week          600--1400 mg/day
  Intervention                    366                        49                     221 (60)       237 (65)         117 (32)              48 weeks             Weeks 4--48                 800 mg 3 times/day          Alpha-2b; 1.5 ug/kg/week   600--1400 mg/day                                                                       
  Control                         363                        49                     206 (57)       227 (63)         121 (33)              48 weeks             --                          --                          Alpha-2b; 1.5 ug/kg/week   600--1400 mg/day                                                                       
  Bacon et al[@b11-tcrm-8-105]    North America and Europe   Experienced            Intervention   162              53                    98 (60)              94 (58)                     66 (41)                     48 weeks                   Weeks 4--36                     800 mg 3 times/day   Alpha-2b; 1.5 ug/kg/week          600--1400 mg/day
  Intervention                    161                        52                     112 (70)       96 (60)          61 (38)               48 weeks             Weeks 4--48                 800 mg 3 times/day          Alpha-2b; 1.5 ug/kg/week   600--1400 mg/day                                                                       
  Control                         80                         53                     58 (72)        46 (58)          34 (42)               48 weeks             --                          --                          Alpha-2b; 1.5 ug/kg/week   600--1400 mg/day                                                                       
  Flamm et al[@b12-tcrm-8-105]    North America              Experienced            Intervention   134              53                    96 (72)              79 (56)                     55 (41)                     48 weeks                   Weeks 4--48                     800 mg 3 times/day   Alpha-2a; 180 ug/week             1000--1200 mg/day
  Control                         67                         52                     43 (64)        40 (57)          27 (40)               48 weeks             --                          --                          Alpha-2a; 180 ug/week      1000--1200 mg/day                                                                      

**Abbreviations:** HCV, hepatitis C virus; no, number.

###### 

Study characteristics of the telaprevir trials

  Trial                                Region          Treatment experience   Arm            No of patients   Age in years -- median   Male sex -- no (%)   HCV genotype 1a -- no (%)   HCV genotype 1b -- no (%)   Total treatment duration   Telaprevir treatment duration   Telaprevir dose      Pegylated interferon alpha dose   Ribavirin dose
  ------------------------------------ --------------- ---------------------- -------------- ---------------- ------------------------ -------------------- --------------------------- --------------------------- -------------------------- ------------------------------- -------------------- --------------------------------- -------------------
  Hezode et al[@b7-tcrm-8-105]         Europe          Naïve                  Intervention   82               44                       49 (60)              37 (45)                     45 (55)                     12 weeks                   Weeks 1--12                     750 mg 3 times/day   Alpha-2a; 180 ug/week             1000--1200 mg/day
  Intervention                         81              46                     54 (67)        31 (38)          50 (62)                  24 weeks             Weeks 1--12                 750 mg 3 times/day          Alpha-2a; 180 ug/week      1000--1200 mg/day                                                                      
  Control                              82              45                     46 (56)        35 (43)          45 (55)                  48 weeks             --                          --                          Alpha-2a; 180 ug/week      1000--1200 mg/day                                                                      
  McHutchison et al[@b9-tcrm-8-105]    North America   Naïve                  Intervention   17               49                       12 (71)              9 (53)                      6 (35)                      12 weeks                   Weeks 1--12                     750 mg 3 times/day   Alpha-2a; 180 ug/week             1000--1200 mg/day
  Intervention                         79              49                     54 (68)        53 (67)          17 (22)                  24 weeks             Weeks 1--12                 750 mg 3 times/day          Alpha-2a; 180 ug/week      1000--1200 mg/day                                                                      
  Intervention                         79              50                     48 (61)        48 (61)          27 (34)                  48 weeks             Weeks 1--12                 750 mg 3 times/day          Alpha-2a; 180 ug/week      1000--1200 mg/day                                                                      
  Control                              75              49                     43 (57)        50 (67)          20 (27)                  48 weeks             --                          --                          Alpha-2a; 180 ug/week      1000--1200 mg/day                                                                      
  Jacobson et al[@b8-tcrm-8-105]       International   Naïve                  Intervention   363              49                       214 (59)             213 (59)                    149 (41)                    48 weeks                   Weeks 1--12                     750 mg 3 times/day   Alpha-2a; 180 ug/week             1000--1200 mg/day
  Intervention                         364             49                     211 (58)       210 (58)         151 (41)                 48 weeks             Weeks 1--8                  750 mg 3 times/day          Alpha-2a; 180 ug/week      1000--1200 mg/day                                                                      
  Control                              361             49                     211 (58)       208 (58)         151 (42)                 48 weeks             --                          --                          Alpha-2a; 180 ug/week      1000--1200 mg/day                                                                      
  Kumada et al[@b10-tcrm-8-105]        Asia            Naïve                  Intervention   126              53                       66 (52)              2 (2)                       124 (98)                    24 weeks                   Weeks 1--12                     750 mg 3 times/day   Alpha-2b; 1.5 ug/kg/week          600--1000 mg/day
  Control                              63              55                     33 (52)        0                63 (100)                 48 weeks             --                          --                          Alpha-2b; 1.5 ug/kg/week   600--1000 mg/day                                                                       
  McHutchison et al[@b13-tcrm-8-105]   International   Experienced            Intervention   115              51                       78 (68)              69 (60)                     33 (29)                     24 weeks                   Weeks 1--12                     750 mg 3 times/day   Alpha-2a; 180 ug/week             1000--1200 mg/day
  Intervention                         113             52                     80 (71)        61 (54)          42 (37)                  48 weeks             Weeks 1--24                 750 mg 3 times/day          Alpha-2a; 180 ug/week      1000--1200 mg/day                                                                      
  Control                              114             50                     76 (67)        71 (62)          34 (30)                  48 weeks             --                          --                          Alpha-2a; 180 ug/week      1000--1200 mg/day                                                                      
  Zeuzem et al[@b14-tcrm-8-105]        International   Experienced            Intervention   266              51                       183 (69)             118 (44)                    121 (45)                    48 weeks                   Weeks 1--12                     750 mg 3 times/day   Alpha-2a; 180 ug/week             1000--1200 mg/day
  Intervention                         264             51                     189 (72)       121 (46)         115 (44)                 48 weeks             Weeks 5--16                 750 mg 3 times/day          Alpha-2a; 180 ug/week      1000--1200 mg/day                                                                      
  Control                              132             50                     88 (67)        59 (45)          59 (45)                  48 weeks             --                          --                          Alpha-2a; 180 ug/week      1000--1200 mg/day                                                                      

**Abbreviations:** HCV, hepatitis C virus; no, number.

###### 

Direct comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, or discontinuing treatment in the trial intervention (boceprevir provided at a dose of 800 mg three times per day during weeks 4--48 of a 48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks)

  Trial                              Intervention   Control          Relative risk (95% CI)                    
  ---------------------------------- -------------- ---------------- ------------------------ ---------------- -------------------
  **Sustained virologic response**                                                                             
  Naïve patients                                                                                               
   Kwo et al[@b6-tcrm-8-105]         77/103         70% (61%--77%)   39/104                   38% (33%--42%)   1.91 (1.65--2.21)
   Poordad et al[@b5-tcrm-8-105]     242/366        137/363                                                    
  Experienced patients                                                                                         
   Bacon et al[@b11-tcrm-8-105]      107/161        65% (60%--71%)   17/80                    21% (15%--28%)   3.09 (2.24--4.28)
   Flamm et al[@b12-tcrm-8-105]      86/134         14/67                                                      
  **Relapse**                                                                                                  
  Naïve patients                                                                                               
   Kwo et al[@b6-tcrm-8-105]         2/81           6% (1%--14%)     12/53                    23% (17%--28%)   0.24 (0.06--1.00)
   Poordad et al[@b5-tcrm-8-105]     24/265         39/176                                                     
  Experienced patients                                                                                         
   Bacon et al[@b11-tcrm-8-105]      14/121         12% (8%--17%)    8/25                     33% (21%--47%)   0.36 (0.20--0.62)
   Flamm et al[@b12-tcrm-8-105]      11/95          7/21                                                       
  **Discontinuation**                                                                                          
  Naïve patients                                                                                               
   Kwo et al[@b6-tcrm-8-105]         27/103         34% (21%--49%)   52/104                   54% (49%--60%)   0.65 (0.47--0.89)
   Poordad et al[@b5-tcrm-8-105]     151/366        204/363                                                    
  Experienced patients                                                                                         
   Bacon et al[@b11-tcrm-8-105]      55/161         37% (31%--44%)   55/80                    69% (61%--76%)   0.54 (0.45--0.65)
   Flamm et al[@b12-tcrm-8-105]      55/134         47/67                                                      

**Abbreviation:** CI, confidence interval.

###### 

Direct comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, or discontinuing treatment in the trial intervention (telaprevir provided at a dose of 750 mg three times per day during weeks 1--12 of a 48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks)

  Trial                                Intervention   Control          Relative risk (95% CI)                    
  ------------------------------------ -------------- ---------------- ------------------------ ---------------- -------------------
  **Sustained virologic response**                                                                               
  Naïve patients                                                                                                 
   Jacobson et al[@b8-tcrm-8-105]      271/363        72% (65%--79%)   158/361                  43%(39%--48%)    1.69 (1.50--1.91)
   McHutchison et al[@b9-tcrm-8-105]   53/79          31/75                                                      
  Experienced patients                                                                                           
   Zeuzem et al[@b14-tcrm-8-105]       171/266        64% (60%--68%)   22/132                   17%(13%--22%)    3.86 (2.92--5.09)
  **Relapse**                                                                                                    
  Naïve patients                                                                                                 
   Jacobson et al[@b8-tcrm-8-105]      27/314         8% (6%--11%)     64/229                   27% (22%--33%)   0.30 (0.20--0.45)
   McHutchison et al[@b9-tcrm-8-105]   3/51           8/35                                                       
  Experienced patients                                                                                           
   Zeuzem et al[@b14-tcrm-8-105]       26/204         13% (10%--16%)   33/55                    60% (51%--69%)   0.21 (0.16--0.29)
  **Discontinuation**                                                                                            
  Naïve patients                                                                                                 
   Jacobson et al[@b8-tcrm-8-105]      80/363         26% (17%--36%)   159/361                  34% (15%--55%)   0.81 (0.30--2.22)
   McHutchison et al[@b9-tcrm-8-105]   25/79          17/75                                                      
  Experienced patients                                                                                           
   Zeuzem et al[@b14-tcrm-8-105]       100/266        38% (34%--42%)   82/132                   62% (56%--68%)   0.61 (0.52--0.70)

**Abbreviation:** CI, confidence interval.

###### 

Adjusted indirect comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, or discontinuing treatment in the standard dose-duration interventions boceprevir and telaprevir

                                     Boceprevir          Telaprevir          Relative risk (95% CI)   *P* value
  ---------------------------------- ------------------- ------------------- ------------------------ -----------
  **Sustained virologic response**                                                                    
  Patients                                                                                            
   Naïve                             1.91 (1.65--2.21)   1.69 (1.50--1.91)   1.14 (0.93--1.37)        0.20
   Experienced                       3.09 (2.24--4.28)   3.86 (2.92--5.09)   0.81 (0.52--1.23)        0.30
  **Relapse**                                                                                         
  Patients                                                                                            
   Naïve                             0.24 (0.06--1.00)   0.30 (0.20--0.45)   0.80 (0.18--3.45)        0.77
   Experienced                       0.36 (0.20--0.62)   0.21 (0.16--0.29)   1.71 (0.90--3.24)        0.10
  **Discontinuation**                                                                                 
  Patients                                                                                            
   Naïve                             0.65 (0.47--0.89)   0.81 (0.30--2.22)   0.80 (0.28--2.29)        0.72
   Experienced                       0.54 (0.45--0.65)   0.61 (0.52--0.70)   0.88 (0.69--1.12)        0.30

**Abbreviation:** CI, confidence interval.

###### 

Adjusted indirect comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, or discontinuing treatment in the response-guided therapy interventions boceprevir and telaprevir

                                     Boceprevir          Telaprevir          Relative risk (95% CI)   *P* value
  ---------------------------------- ------------------- ------------------- ------------------------ -----------
  **Sustained virologic response**                                                                    
  Patients                                                                                            
   Naïve                             1.69 (1.44--1.96)   1.71 (1.50--1.95)   1.00 (0.82--1.23)        0.87
   Experienced                       2.76 (1.81--4.35)   --                  --                       --
  **Relapse**                                                                                         
  Patients                                                                                            
   Naïve                             0.42 (0.30--0.59)   0.32 (0.24--0.43)   1.31 (0.84--2.05)        0.25
   Experienced                       0.48 (0.29--0.80)   --                  --                       --
  **Discontinuation**                                                                                 
  Patients                                                                                            
   Naïve                             0.67 (0.60--0.75)   0.62 (0.54--0.72)   1.08 (0.90--1.21)        0.60
   Experienced                       0.47 (0.39--0.56)   --                  --                       --

**Abbreviation:** CI, confidence interval.

###### 

Adjusted indirect comparison of adverse events between boceprevir and telaprevir standard dose-duration therapy interventions

                    Boceprevir          Telaprevir          Relative risk (95% CI)   *P* value
  ----------------- ------------------- ------------------- ------------------------ -----------
  **Anemia**                                                                         
  Patients                                                                           
   Naïve            1.63 (1.39--1.92)   1.51 (0.88--2.61)   1.08 (0.61--1.90)        0.79
   Experienced      1.30 (0.42--4.03)   1.96 (1.43--2.68)   0.66 (0.21--2.14)        0.49
  **Neutropenia**                                                                    
  Patients                                                                           
   Naïve            1.51 (0.85--2.68)   0.81 (0.54--1.04)   1.86 (0.96--3.61)        0.06
   Experienced      0.86 (0.60--1.23)   1.35 (0.90--2.02)   0.64 (0.37--1.09)        0.10
  **Rash**                                                                           
  Patients                                                                           
   Naïve            1.05 (0.87--1.27)   1.49 (1.24--1.80)   0.70 (0.54--0.92)        0.01
   Experienced      1.99 (1.06--3.72)   1.97 (1.50--2.58)   1.01 (0.51--2.00)        0.98
  **Pruritus**                                                                       
  Patients                                                                           
   Naïve            0.95 (0.80--1.13)   1.41 (1.20--1.66)   0.67 (0.53--0.85)        0.001
   Experienced      1.10 (0.73--1.65)   1.90 (1.54--2.35)   0.58 (0.37--0.92)        0.02

**Abbreviations:** CI, confidence interval.

###### 

Adjusted indirect comparison of adverse events between boceprevir and telaprevir response-guided therapy duration interventions

                    Boceprevir          Telaprevir          Relative risk (95% CI)   *P* value
  ----------------- ------------------- ------------------- ------------------------ -----------
  **Anemia**                                                                         
  Patients                                                                           
   Naïve            1.68 (1.47--1.92)   1.96 (1.64--2.33)   0.86 (0.69--1.07)        0.17
   Experienced      2.16 (1.55--3.02)   --                  --                       --
  **Neutropenia**                                                                    
  Patients                                                                           
   Naïve            1.18 (0.98--1.42)   0.81 (0.65--1.02)   1.46 (1.09--1.95)        0.05
  **Rash**                                                                           
  Patients                                                                           
   Naïve            1.11 (0.92--1.33)   1.48 (1.26--1.74)   0.75 (0.59--0.96)        0.02
   Experienced      3.33 (1.63--6.83)   --                  --                       --
  **Pruritus**                                                                       
  Patients                                                                           
   Naïve            0.88 (0.73--1.04)   1.31 (1.16--1.48)   0.67 (0.54--0.83)        0.0003
   Experienced      1.06 (0.70--1.59)   --                  --                       --

**Abbreviation:** CI, confidence interval.
